CPT 81464 Reimbursement & Benchmarks

CPT code 81464 is a specialized molecular pathology procedure used to analyze genomic sequence variants in solid organ neoplasms through cell-free nucleic acid, such as plasma. This test is increasingly important in oncology, offering non-invasive insights into tumor genetics that can inform diagnosis, prognosis, and targeted therapy decisions. The code is relevant for laboratories performing advanced genomic sequencing, and its adoption reflects the growing role of precision medicine in cancer care.

Major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare provide coverage for this procedure, underscoring its clinical significance and widespread utilization. Readers will gain an understanding of the clinical context for 81464, including its role in molecular diagnostics, typical laboratory settings, and how it fits within broader genomic sequencing services. The publication also covers related CPT codes, common modifiers, and associated taxonomies, offering a comprehensive overview of billing and policy considerations for this advanced test.

Key benchmarks, policy updates, and clinical applications are discussed, providing stakeholders with actionable insights into the evolving landscape of molecular pathology and laboratory genomics. This summary serves as a resource for understanding the national importance of 81464 in cancer diagnostics and its integration into payer coverage policies.

CPT Code Overview

CPT code 81464 represents a genomic sequence analysis panel for solid organ neoplasms, specifically utilizing cell-free nucleic acid (such as plasma) to interrogate for sequence variants. This procedure falls under molecular pathology and genomic sequencing procedures within the field of pathology and laboratory medicine. The typical site of service for this test is a laboratory setting, designated as Place of Service 81. This advanced molecular diagnostic tool is used to detect genetic alterations in solid organ tumors, providing critical information for clinical decision-making and personalized treatment strategies.

Clinical Context

A patient with a suspected or confirmed solid organ neoplasm, such as a malignant tumor of the lip or tongue, presents to their oncologist or surgeon. The clinician orders a genomic sequence analysis panel on cell-free nucleic acid (e.g., plasma) to interrogate for sequence variants. This test, represented by CPT code 81464, is performed in a laboratory setting (Place of Service 81). The results help guide diagnosis, prognosis, or targeted therapy decisions. The workflow involves specimen collection (typically blood), laboratory processing, and interpretation by a specialist in medical genetics or molecular pathology.

Coding Specifications

Modifiers:
- Modifier 26: Used when reporting only the professional component of the service (interpretation of results).
- Modifier TC: Used when reporting only the technical component (laboratory processing and analysis).
Provider Taxonomies:

Taxonomy Code Specialty Name

National mean rates for CPT code 81464 among commercial payers show that UnitedHealth Group has the highest average reimbursement at $2,606.14, while Cigna is the lowest at $1,525.21. The BUCA (average commercial) mean rate stands at $2,366.73. Medicare rates are not available in the input for comparison.

Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Cigna exhibits the widest spread ($2,350.13), indicating substantial variability in contracted rates. Blue Cross Blue Shield also shows a large range ($2,145.50), while Aetna's rates are more tightly clustered ($975.00). UnitedHealth Group and BUCA have moderate dispersion, at $1,529.50 and $1,232.20 respectively.

The table and chart below present a detailed breakdown of national benchmarks for each payer, including mean rates and percentile values.

Related Diagnoses

C00.0: Malignant neoplasm of external upper lip
- Relevant for patients with cancer located on the external upper lip, where genomic sequencing may inform treatment.
C00.1: Malignant neoplasm of external lower lip
- Applies to cancers of the external lower lip, guiding targeted therapy decisions.
C00.2: Malignant neoplasm of external lip, unspecified
- Used when the specific external lip site is not detailed, but sequencing is clinically indicated.
C00.3: Malignant neoplasm of upper lip, inner aspect
- For tumors on the inner aspect of the upper lip, sequencing can help identify actionable variants.
C00.4: Malignant neoplasm of lower lip, inner aspect
- Relevant for inner lower lip cancers, supporting personalized medicine approaches.
C00.5: Malignant neoplasm of lip, unspecified, inner aspect
- Used when the inner aspect is involved but not further specified.
C00.6: Malignant neoplasm of commissure of lip, unspecified
- For cancers at the lip commissure, sequencing may assist in diagnosis and management.
C00.8: Malignant neoplasm of overlapping sites of lip
- Applies when the tumor spans multiple lip sites, requiring comprehensive genomic analysis.
C00.9: Malignant neoplasm of lip, unspecified
- Used for unspecified lip cancers, where sequencing is part of the diagnostic workup.
C01: Malignant neoplasm of base of tongue
- Relevant for tongue base cancers, sequencing may reveal targetable mutations.
C02.0: Malignant neoplasm of dorsal surface of tongue
- For tumors on the dorsal tongue, genomic analysis can inform therapy.
C02.1: Malignant neoplasm of border of tongue
- Applies to cancers at the tongue border, sequencing may guide treatment.
C02.2: Malignant neoplasm of ventral surface of tongue
- For ventral tongue cancers, sequencing is used for variant detection.
C02.3: Malignant neoplasm of anterior two-thirds of tongue, part unspecified
- Used when the anterior tongue is involved but not further specified.
C02.4: Malignant neoplasm of lingual tonsil
- For lingual tonsil cancers, sequencing may identify relevant mutations.
C02.8: Malignant neoplasm of overlapping sites of tongue
- Applies when the tumor involves multiple tongue sites, requiring broad genomic analysis.
C02.9: Malignant neoplasm of tongue, unspecified
- Used for unspecified tongue cancers, sequencing is part of the diagnostic and therapeutic workflow.

Related CPT Codes

81455: Genomic sequencing procedures for somatic alterations in neoplasms (other context). Used for broader or different panels targeting somatic mutations in neoplasms.
81456: Genomic sequencing procedures for somatic alterations—RNA analysis separate method. Used when RNA-based analysis is required in addition to or instead of DNA-based testing.
81459: Genomic sequencing procedures, multianalyte with TMB/MSI (combined analyses). Used when tumor mutational burden or microsatellite instability analyses are needed alongside sequencing.
0250U: Proprietary laboratory analysis code in the same coverage group. Represents a specific lab-developed test related to neoplasm sequencing.
0326U: Proprietary laboratory analysis code in the same coverage group. Another specific lab-developed test for neoplasm sequencing.
0334U: Proprietary laboratory analysis code in the same coverage group. Used for a unique panel or method for neoplasm sequencing.
0473U: Proprietary laboratory analysis code in the same coverage group. Represents a specialized test for neoplasm sequencing.

These codes may be used as alternatives or in conjunction with 81464 depending on the clinical scenario, specimen type, or specific analysis required.

The table and chart below present a detailed breakdown of national benchmarks for each payer, including mean rates and percentile values.

OpenPayer

Summary & Overview

CPT 81464: Genomic Sequencing Panel for Solid Organ Neoplasms